MEXICO CITY, Feb. 25, 2026 /PRNewswire/ — Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the fourth quarter and full year 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.
Comments from Genomma’s CEO, Marco Sparvieri
“2025 was a challenging year, with like-for-like sales declining -4.3% due to a weak summer beverage season in Mexico, a softer overall consumption environment in the country, and execution gaps. Q4 like-for-like sales decreased -12.9% due to the Company’s decision to significantly reduced Mexico Q4 sell-in to normalize elevated retailer inventories following two weak OTC and beverage seasons. Importantly, Q4 Mexico sell-out declined a moderate -2.2%, confirming that underlying consumer demand remains resilient. Despite topline pressure, Genomma Lab delivered a resilient year-end 23.4% EBITDA margin and maintained a healthy 107-day cash-conversion cycle, underscoring the strength of our business fundamentals, disciplined execution and cost containment across the organization. We responded decisively by unlocking MXN 1.1 billion in productivity savings to reinvest in our growth initiatives: product innovation, distribution expansion, enhanced in-store execution and stronger communication. While early 2026 will reflect higher OPEX and softer sales, we expect growth initiatives to gain traction in the second half of the year, supporting a recovery in operational leverage. 2025’s downturn was cyclical, not structural, and our fundamentals remain solid. As we rebuild momentum for our next phase of sustained growth, Genomma Lab is well-positioned to emerge stronger from this cycle.”
Q4 2025 and Full Year Financial Summary
The following table provides a summary of the Company’s Income Statement, in millions of Mexican pesos.
Net Sales: Decreased by -5.7% in 2025 primarily reflecting a weak summer beverage season in Mexico, a softer consumption environment in the country and hyperinflationary effects. Net sales decreased -13.9% in Q4 2025 primarily due to FX headwinds and an intentional -22.1% reduction in Mexico sell-in to normalize elevated retailer inventories following two weak OTC and beverage seasons. Mexico sell-out declined a moderate -2.2% during the quarter, confirming that underlying consumer demand remains resilient.
EBITDA: Reached a 23.4% margin in 2025; a +43 basis-point increase driven by successful company-wide productivity initiatives, reflecting strong operational resilience despite deleveraging pressures. EBITDA reached a 22.1% margin in Q4 2025 as lower SG&A partially offset the operational deleverage following the significant reduction in Mexico sell-in during the quarter.
Net Income from Continuous Operations: Decreased by -23.1% in full year 2025 despite lower net interest expense due to higher non-cash foreign exchange losses primarily related to a -42% depreciation of the Argentine peso. Net income from continuous operations declined -13.0% in Q4 2025 despite lower net interest expense and lower non-cash exchange losses due to higher taxes.
CONFERENCE CALL INFORMATION
Date: Thursday, February 26, 2026
Time: 12:00 p.m. ET | 11:00 a.m. Mexico City Time
Webcast Registration: Genomma’s Q4 & FY 2025 Earnings Call
Participants: Marco Sparvieri, CEO
Antonio Zamora, CFO
Christianne Ibanez, IRO After registration, please use the Zoom link provided to ensure optimal access to the event webcast and to avoid difficulties associated with local carrier connections. Sell-side Analyst Coverage As of February 25, 2026 “LABB” is covered by 8 sell-side analysts at the following brokerages: Actinver Casa de Bolsa, Banco Itaú BBA, BBVA Bancomer, BTG Pactual US Capital, GBM Grupo Bursátil Mexicano, Grupo Financiero Banorte, J.P. Morgan Securities and Monex Grupo Financiero. About
Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “LAB B” (Bloomberg: LABB:MM). Note on Forward-Looking Statements This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company’s related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE Genomma Lab Internacional, S.A.B. de C.V.
|
Q4 2025 |
% sales |
Q4 2024 |
% sales |
var % |
2025 |
% sales |
2024 |
% sales |
var % |
|
|
Like-for-like Sales(1) |
-12.9 % |
-4.3 % |
||||||||
|
Net Sales |
4,017.0 |
100 % |
4,665.6 |
100 % |
-13.9 % |
17,541.2 |
100 % |
18,606.9 |
100 % |
-5.7 % |
|
Gross Profit |
2,449.2 |
61.0 % |
2,941.7 |
63.1 % |
-16.7 % |
11,022.1 |
62.8 % |
11,931.0 |
64.1 % |
-7.6 % |
|
Operating Income |
800.6 |
19.9 % |
953.1 |
20.4 % |
-16.0 % |
3,759.6 |
21.4 % |
3,922.5 |
21.1 % |
-4.2 % |
|
Adjusted EBITDA(2) |
886.6 |
22.1 % |
1,121.7 |
24.0 % |
-21.0 % |
4,100.9 |
23.4 % |
4,330.3 |
23.3 % |
-5.3 % |
|
EBITDA(3) |
886.6 |
22.1 % |
1,061.7 |
22.8 % |
-16.5 % |
4,100.9 |
23.4 % |
4,270.3 |
23.0 % |
-4.0 % |
|
Net Income from |
319.6 |
8.0 % |
367.3 |
7.9 % |
-13.0 % |
1,607.4 |
9.2 % |
2,091.1 |
11.2 % |
-23.1 % |
|
EPS from Continuous Operations |
0.32 |
0.37 |
-13.0 % |
1.61 |
2.09 |
-23.1 % |
|
(1) |
Like-for-like (“LFL”) Sales are Net Sales expressed in constant currency and excludes the hyperinflationary subsidiary |
||
|
(2) |
Excludes effects from discontinued operations in 2024. |
||
|
(3) |
EBITDA defined as operating income before depreciation and amortization |
Antonio Zamora, CFO
Christianne Ibanez, IRO After registration, please use the Zoom link provided to ensure optimal access to the event webcast and to avoid difficulties associated with local carrier connections. Sell-side Analyst Coverage As of February 25, 2026 “LABB” is covered by 8 sell-side analysts at the following brokerages: Actinver Casa de Bolsa, Banco Itaú BBA, BBVA Bancomer, BTG Pactual US Capital, GBM Grupo Bursátil Mexicano, Grupo Financiero Banorte, J.P. Morgan Securities and Monex Grupo Financiero. About
Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “LAB B” (Bloomberg: LABB:MM). Note on Forward-Looking Statements This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company’s related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Source link
Leave a Reply